



Public Formulary Overview – NFLD and Labrador

December 2021

Formulation	Trade Name	Coverage
Long-Acting Stimulants	Adderal XR	Covered – No Restrictions
	Concerta / ER MPH / ER-C	Covered – No Restrictions
	Biphentin – 80mg max	Special Authorization
	Vyvanse – 60 mg max	
	<p>For patients who have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers and/or societal barriers, AND; Have been tried on methylphenidate (immediate release or long-acting formulation) or dexamphetamine (immediate release or long-acting formulation) with unsatisfactory results. Refer to maximum billable dose as listed. Reimbursement will not be considered for Biphentin, Concerta and/or Vyvanse concurrently with methylphenidate (immediate release or long-acting formulation).</p> <p>*Please note claims for Concerta brand will be reimbursed up to the cost of generic methylphenidate ER.</p> <p><i>*Note from CADDRA. Administrative barriers may include things like difficulty or resistance from school personnel in dispensing medication. Societal barriers may include difficulties surrounding stigma, especially within the context of the school environment.</i></p>	
	Foquest	Not Covered
Short Acting Stimulants	Ritalin	Covered – No Restrictions
	Ritalin SR	
	Dexedrine	
	Dexedrine Spansules	
Non-Stimulant Medications	Strattera	Covered – No restrictions
	Intuniv XR	

Information retrieved from the province of Newfoundland and Labrador in December 2021, [click here](#) to access the most up to date coverage information. [Special Authorization](#) form must be submitted when applicable. for more information on special authorization, [click here](#).